PT - JOURNAL ARTICLE AU - Praetorius, Teresa H. AU - Leonova, Anna AU - Lac, Vivian AU - Senz, Janine AU - Tessier-Cloutier, Basile AU - Nazeran, Tayyebeh M. AU - Köbel, Martin AU - Grube, Marcel AU - Kraemer, Bernhard AU - Yong, Paul J. AU - Kommoss, Stefan AU - Anglesio, Michael S. TI - Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes AID - 10.1101/2021.04.12.21255355 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.12.21255355 4099 - http://medrxiv.org/content/early/2021/11/30/2021.04.12.21255355.short 4100 - http://medrxiv.org/content/early/2021/11/30/2021.04.12.21255355.full AB - Endometriosis symptoms are heterogeneous with controversy on whether it constitutes a single disease or multiple distinct types. Our previous work found recurrent somatic cancer-driver alterations in endometriosis; however, these have not been found ubiquitously. A handful of cases spread across studies also suggest mutations might be shared (clonal) between lesions of the same type. As current classification systems correlate poorly with symptoms or outcomes, somatic genomics may improve the current system. Here, we investigate heterogeneity of somatic cancer-driver mutations within patients and across endometriosis types. We examined anatomically distinct types of endometriosis (ovarian, deep infiltrating, and superficial endometriosis) in 27 individual patients all of whom had at least two types of endometriosis. Specimens were analyzed using high-sensitivity targeted sequencing with orthogonal validation from droplet digital PCR and mutation-surrogate immunohistochemistry. Results found 13/27 patients had informative somatic driver mutation in endometriosis, 9/13 had identical mutations across distinct lesions. Endometriomas tended to have a higher mutational complexity, with functionally redundant driver mutations in same gene and within the same lesions.Our data are consistent with clonality across endometriosis lesions regardless of subtype. Further the finding of redundancy in mutations with the same gene and lesions is also consistent with endometriosis representing an oligoclonal disease with dissemination likely to consist of multiple epithelial clones travelling together. This suggests the current anatomically defined classification of endometriosis does not fully recognize the etiology of the disease. A novel classification should take into account genomic and other molecular features. These findings could further contribute to development of a more personalized endometriosis diagnosis and care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMajor funding was provided by Canadian Institutes of Health Research (Early Career Investigator Grant in in Maternal, Reproductive, Child & Youth Health to M.S. Anglesio) M. Koebel received support through the Calgary Laboratory Services research support fund (RS19-609). M.S. Anglesio is funded through a Michael Smith Foundation for Health Research Scholar Award and the Janet D. Cottrelle Foundation Scholars program (managed by the BC Cancer Foundation). This project received technical and data management support from Calgary Laboratory Services and the Genetic Pathology Evaluation Centre (GPEC). GPEC receive core support from BC's Gynecological Cancer Research team (OVCARE), and the VGH&UBC Hospital Foundation. Dr. M Koebel was supported by internal research support (RS19-621). Funders did not have input on research design, collection of data, interpretation of results, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Tuebingen University Hospital Research Ethics Board approved collection and use of the materials. The University of British Columbia research ethics board approved the use of specimen in research. The project was conducted in compliance with the Canadian Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans (TCPS2, 2018), effort to obtain written informed consent was exercised for all patients. Specimen from non-contactable patients (lost contact/deceased) treated more than 5 years before the start of the study were included under institutionally approved waiver of consent (Tuebingen University Hospital Research Ethics Board).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is contained within the manuscript and/or associated supplemental information.